Inspiration Healthcare Group PLC Distribution agreement for AIHL test (7232K)
April 24 2020 - 2:00AM
UK Regulatory
TIDMIHC TIDMGDR
RNS Number : 7232K
Inspiration Healthcare Group PLC
24 April 2020
Inspiration Healthcare Group plc
("Inspiration Healthcare", the "Company" or the "Group")
Inspiration Healthcare to distribute genedrive's Antibiotic
Induced Hearing Loss test in UK and Ireland
Inspiration Healthcare Group plc (AIM: IHC), the global medical
technology company, is pleased to announce that it has entered into
a contract with genedrive plc (AIM: GDR), the near patient
molecular diagnostics company, to distribute its Antibiotic Induced
Hearing Loss test (Genedrive(R) MT-RNR1) in the UK and Ireland. It
is expected that the scope of the contract between genedrive and
Inspiration Healthcare will be expanded over time to engage
Inspiration Healthcare's specialty network of over 50 neonatal
focussed sub-distributors around the world.
Neil Campbell, Chief Executive Officer of Inspiration Healthcare
commented "We are delighted to be able to work with genedrive plc
with this novel testing device for new born babies that could
suffer hearing loss due to anti-biotics given to them on admission
into neonatal intensive care. Our focus has always been products
that can have a profound effect on the patient outcome and we look
forward to working with genedrive to make this test the standard of
care in the UK and the wider neonatal community around the
world."
The Genedrive (R) MT-RNR1 test is the world's first
point-of-care genetic test designed for use in a neonatal intensive
care setting. The test screens newborns for a genetic mutation
called mt-RNR1 that can cause lifelong and irreversible deafness to
a child upon administration of certain antibiotics. In the UK,
90,000 babies are admitted to NICU units each year, and 80-85% of
them receive antibiotics. Genedrive's rapid genetic test can be
completed in less than 30 minutes, allowing for correct treatment
decision on antibiotics to be made within one hour of admission, as
required by the UK's National Institute of Clinical Excellence
(NICE)
David Budd, Chief Executive Officer of genedrive plc, said: "Our
agreement with Inspiration Healthcare combines genedrive's
innovative first-to-market AIHL product, with a thought leading
healthcare company with a specialist emphasis on neonatal care.
Inspiration Healthcare has a strong track record in the
introduction of new technologies and over many years they have
developed an extensive network of key opinion leaders that will be
very beneficial as we bring the Genedrive AIHL test to market
together."
Enquiries:
Inspiration Healthcare Tel: 01455 840555
Group plc
Neil Campbell, Chief Executive
Officer
Mike Briant, Chief Financial
Officer
Jon Ballard, Financial
Controller
Nominated Adviser & Broker Tel: 0207 397 8900
Cenkos Securities plc
Mark Connelly
Stephen Keys
Cameron MacRitchie
Cadogan PR Tel: 07771 713608
Alex Walters
alex.walters@cadoganpr.com
About Inspiration Healthcare http://www.inspiration-healthcare.com
Inspiration Healthcare is a global provider of medical
technology for use in critical care & operating theatres. The
Company provides high quality innovative products to patients
around the world which help to improve patient outcomes and it
actively invests in innovative product opportunities and disruptive
technologies.
Through investment in research and development the Company has 6
key own brand products that can be used within the first 6 hours of
life to help premature and sick babies; helping with assessment,
resuscitation, stabilisation as well as preventing brain damage.
Additionally the Company has its own range of products for
maintaining normothermia pre, during and post-surgery.
With product availability extending to over 50 countries through
a distribution network, Inspiration Healthcare's success has been
built on continuous innovation, excellent customer service and an
inherent commitment to improving patient outcomes, working in close
collaboration with key opinion leaders across the globe. In the UK
and Ireland the Company has a direct sales team selling Inspiration
Branded and complementary products from third parties, with an
additional range of home healthcare products. This is supported by
Technical Support for planned preventative maintenance and
emergency assistance. Further information on Inspiration Healthcare
can be seen at www.inspiration-healthcare.com
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Company has assays on market for the detection of
HCV, certain military biological targets, Antibiotic Induced
Hearing Loss, and has tests in development for tuberculosis (mTB)
and SARS-CoV-2.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRFFFVISEIVFII
(END) Dow Jones Newswires
April 24, 2020 02:00 ET (06:00 GMT)
Inspiration Healthcare (LSE:IHC)
Historical Stock Chart
From Apr 2024 to May 2024
Inspiration Healthcare (LSE:IHC)
Historical Stock Chart
From May 2023 to May 2024